

**Wanbury Limited**

Regd. Office : BSEL Tech Park, B-wing
10th Floor, Sector-30 A,
Opp. Vashi Railway Station,
Vashi Navi Mumbai 400 703
Maharashtra, INDIA
Tel. : +91-22-6794 2222
+91-22-7196 3222
CIN L51900MH1988PLC048455
Email : info@wanbury.com
Website : www.wanbury.com

May 16, 2024

BSE Limited
PJ. Towers,
Dalal Street
Mumbai-400001
Script Code: 524212

National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East),
Mumbai -400051
Script Code: WANBURY

Sub.: Press release on Q4 & FY24 Financial Results

Dear Sir/Madam,

Please find attached herewith copy of press release on Q4 & FY24 Financial Results.

This is for your information and record.

Thanking you.

Yours faithfully,
For Wanbury Ltd



Jitendra Gandhi
Company Secretary

Encl. a/a.



Wanbury Ltd. net profit up 696% (YOY) at Rs. 8.3 cr in Q4FY24

16th May, 2024, MUMBAI: Wanbury Ltd, one of India's fastest growing pharmaceutical company having a presence in API global market and domestic branded Formulation, announced its financial results for the fourth quarter and year ended March 31, 2024.

Consolidated Q4 & FY24 Financial Highlights

Particulars	(Rs in Crore)							
	Q4 FY24	Q3 FY24	% QoQ	Q4 FY23	% YoY	FY24	FY23	% YoY
Revenue from Operations	139.4	145.5	-4.2%	133.0	4.8%	575.6	499.6	15.2%
EBITDA	19.1	21.8	-13%	12.1	57.7%	73.0	24.1	203.1%
EBITDA Margin (%)	13.7%	15.0%	-1.3%	9.1%	4.5%	12.7%	4.8%	7.9%
PAT	8.3	10.3	-18.6%	1.0	696%	30.4	(10.4)	392.4%
PAT Margin (%)	6.0%	7.0%	-1%	0.8%	5.2%	5.3%	(2.1%)	7.3%

Commenting on the performance, Mr Mohan Rayana, Director, Wanbury Ltd. said, the company registered a 15% growth in Revenue & 4 fold jump in its Net Profits on YOY basis. The company has achieved the same through growth in sales of its key products Metformin & Sertraline. The company has also undertook various measures to improve its profitability like focus on Niche products, cost optimisation via operational excellence , yield improvement etc.

The management is confident of continuing this growth journey in coming quarters through expansion of customer base & increase in SOB of existing customers coupled with development of new APIs and entry into new Therapy segment in Formulation business.





About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact:

Jitendra J. Gandhi
Company Secretary,
Wanbury Limited
BSEL Techpark, B' Wing, 10th Floor,
Sector 30-A, Opp. Vashi Railway Station,
Vashi, Navi Mumbai - 400703, India.
Tel: +91-22-6794 2222
Email: jitendra.gandhi@wanbury.com

Hanishi Shah / Anand Venugopal
Adfactors PR
Oasis Complex, Kamala Mills
Compound, City Hall, Pandurang
Budhkar Marg, Lower Parel West,
Mumbai - 400021
Tel: +91 9619059339 / +91 7021852071
Email: hanishi.shah@adfactorspr.com
anand.venugopal@adfactorspr.com

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.

